Rhodes Pharms patents expiration
1. Aptensio Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10039719 | RHODES PHARMS | Methods of treating attention deficit hyperactivity disorder |
Dec, 2019
(4 years ago) | |
| US9801823 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US8580310 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US7438930 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US7083808 | RHODES PHARMS | Controlled/modified release oral methylphenidate formulations |
Dec, 2019
(4 years ago) | |
| US6419960 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US9066869 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US7247318 | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Dec, 2019
(4 years ago) | |
| US10463624 | RHODES PHARMS | Controlled release formulations |
Dec, 2019
(4 years ago) | |
|
US6419960 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US9066869 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US9801823 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US10039719 (Pediatric) | RHODES PHARMS | Methods of treating attention deficit hyperactivity disorder |
Jun, 2020
(3 years ago) | |
|
US7083808 (Pediatric) | RHODES PHARMS | Controlled/modified release oral methylphenidate formulations |
Jun, 2020
(3 years ago) | |
|
US8580310 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US7438930 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
|
US7247318 (Pediatric) | RHODES PHARMS | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
Jun, 2020
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 17, 2018 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 April, 2015
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of APTENSIO XR before it's drug patent expiration?
More Information on Dosage
APTENSIO XR family patents
2. Dilaudid patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6589960 | RHODES PHARMS | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 1992
Treatment: NA
Dosage: SOLUTION;ORAL; TABLET;ORAL
How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage
DILAUDID family patents